Atrial Fibrillation: A Comprehensive Review of Pathophysiology, Mechanisms, and Emerging Therapeutic Strategies

Abstract

Atrial fibrillation (AF) remains a significant global health challenge, impacting millions and contributing substantially to morbidity and mortality. This comprehensive review delves into the multifaceted nature of AF, examining its underlying pathophysiology, intricate electrophysiological and structural mechanisms, and the diverse clinical manifestations. Beyond the established risk factors and diagnostic approaches, we critically evaluate contemporary treatment strategies, encompassing pharmacological interventions, catheter ablation techniques, and surgical modalities. Furthermore, this review explores the frontiers of AF research, highlighting the potential of novel therapeutic targets, advanced imaging technologies, and innovative ablation strategies, including pulsed field ablation (PFA), to improve patient outcomes and address the persistent limitations of current therapies. This review is intended for expert audiences seeking a detailed and critical analysis of the evolving landscape of AF management.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, characterized by rapid and irregular atrial activation leading to disorganized ventricular contraction [1]. Its prevalence increases with age, affecting an estimated 1-2% of the general population, with projections indicating a substantial rise in the coming decades [2]. The clinical impact of AF extends beyond symptomatic palpitations, as it significantly elevates the risk of stroke, heart failure, cognitive decline, and overall mortality [3]. The economic burden associated with AF management, including hospitalizations, medications, and interventions, poses a significant strain on healthcare systems worldwide [4].

Despite advancements in understanding AF pathophysiology and therapeutic interventions, effective long-term management remains a considerable challenge. Current treatment strategies primarily focus on rate or rhythm control, coupled with anticoagulation to mitigate thromboembolic risk. However, pharmacological approaches often exhibit limited efficacy and are associated with significant side effects [5]. Catheter ablation, a more invasive approach, has emerged as a viable option for rhythm control, particularly in symptomatic patients refractory to drug therapy. Yet, the long-term success rates of catheter ablation vary considerably, and procedural complications remain a concern [6].

This comprehensive review aims to provide an in-depth analysis of AF, encompassing its underlying mechanisms, diagnostic modalities, therapeutic options, and emerging strategies. We will critically evaluate the strengths and limitations of current treatments, explore the potential of novel therapeutic targets, and discuss the role of advanced technologies in improving AF management. The review is structured to provide a contemporary overview of the field, suitable for experts seeking a comprehensive understanding of the complexities and challenges associated with AF.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Pathophysiology and Mechanisms of Atrial Fibrillation

The pathophysiology of AF is complex and multifactorial, involving a dynamic interplay of electrophysiological, structural, and neurohumoral factors [7]. The initiation and maintenance of AF are influenced by several key mechanisms, including:

2.1. Triggered Activity:

Triggered activity refers to abnormal atrial depolarizations that initiate AF, often originating from ectopic foci within the pulmonary veins (PVs) [8]. These foci exhibit enhanced automaticity or triggered activity due to abnormal ion channel function, calcium handling abnormalities, or structural remodeling. The PVs are particularly susceptible to ectopic firing due to the presence of myocardial sleeves extending into the venous wall, creating a substrate for abnormal electrical activity [9].

2.2. Re-entry:

Re-entry is another critical mechanism underlying AF maintenance. It involves the propagation of an electrical impulse through a circuit of excitable tissue, where the impulse re-enters and repeatedly activates the atria. Re-entrant circuits can occur around anatomical obstacles, such as the PV ostia, or within areas of atrial fibrosis or scar tissue [10]. The complexity of atrial anatomy and the presence of heterogeneities in refractoriness facilitate the formation and perpetuation of re-entrant circuits.

2.3. Atrial Remodeling:

Atrial remodeling is a progressive process involving structural, electrical, and contractile changes that promote AF persistence. Structural remodeling includes atrial fibrosis, myocyte hypertrophy, and altered atrial architecture [11]. Fibrosis, in particular, disrupts normal electrical conduction, creating regions of slow conduction and anisotropy that favor re-entrant arrhythmias. Electrical remodeling involves alterations in ion channel expression and function, leading to shortened atrial refractoriness and increased susceptibility to AF [12]. Contractile remodeling encompasses impaired atrial contractility and reduced atrial function, contributing to thromboembolic risk and heart failure.

2.4. Role of Inflammation and Oxidative Stress:

Emerging evidence suggests that inflammation and oxidative stress play a significant role in AF pathogenesis [13]. Inflammatory mediators, such as C-reactive protein (CRP) and interleukin-6 (IL-6), have been associated with increased AF risk and recurrence after ablation. Oxidative stress, resulting from an imbalance between reactive oxygen species (ROS) production and antioxidant defenses, can promote atrial remodeling and exacerbate AF [14]. These factors can contribute to the progression from paroxysmal to persistent AF.

2.5. Autonomic Nervous System Modulation:

The autonomic nervous system (ANS) exerts a profound influence on atrial electrophysiology and AF susceptibility. Both sympathetic and parasympathetic activation can trigger and maintain AF [15]. Sympathetic activation increases heart rate, shortens atrial refractoriness, and enhances triggered activity, while parasympathetic activation can induce bradycardia and promote vagally mediated AF. The balance between sympathetic and parasympathetic tone can be disrupted by various factors, including stress, exercise, and sleep apnea, contributing to AF vulnerability.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Risk Factors and Clinical Manifestations

Several modifiable and non-modifiable risk factors have been identified as independent predictors of AF [16]. These include:

3.1. Non-modifiable Risk Factors:

• Age: The prevalence of AF increases exponentially with age, reflecting the cumulative effects of atrial remodeling and underlying comorbidities.
• Sex: Men are generally more prone to developing AF than women, although the incidence in women increases after menopause.
• Genetics: Genetic factors play a role in AF susceptibility, with several genes implicated in ion channel function, atrial structure, and inflammation [17].

3.2. Modifiable Risk Factors:

• Hypertension: Elevated blood pressure contributes to atrial remodeling and increases AF risk.
• Heart Failure: Heart failure and AF often coexist, with each condition exacerbating the other.
• Obesity: Obesity is associated with increased atrial size, inflammation, and autonomic dysfunction, predisposing to AF.
• Diabetes Mellitus: Diabetes promotes atrial fibrosis and increases AF risk.
• Chronic Kidney Disease: Renal dysfunction is associated with increased inflammation and oxidative stress, contributing to AF pathogenesis.
• Sleep Apnea: Obstructive sleep apnea (OSA) is a common comorbidity in AF patients, with intermittent hypoxia and sleep fragmentation promoting atrial remodeling and autonomic dysfunction [18].
• Alcohol Consumption: Excessive alcohol intake can trigger AF episodes and contribute to long-term atrial remodeling.
• Smoking: Smoking is associated with increased inflammation and oxidative stress, increasing AF risk.

3.3. Clinical Manifestations:

AF can manifest in various ways, ranging from asymptomatic episodes to debilitating symptoms [19]. Common symptoms include:

• Palpitations: A fluttering or racing sensation in the chest.
• Fatigue: Generalized weakness and lack of energy.
• Shortness of Breath: Difficulty breathing, particularly during exertion.
• Dizziness: Lightheadedness or a feeling of faintness.
• Chest Pain: Discomfort or pressure in the chest.

In some cases, AF may present with more severe complications, such as stroke, heart failure, or sudden cardiac death.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Diagnostic Methods

The diagnosis of AF relies on the documentation of irregular atrial activity on an electrocardiogram (ECG) [20]. Various diagnostic tools are available to detect and characterize AF, including:

4.1. Electrocardiogram (ECG):

The standard 12-lead ECG is the cornerstone of AF diagnosis. It demonstrates the absence of P waves and the presence of irregular R-R intervals, indicative of chaotic atrial activity.

4.2. Holter Monitoring:

Holter monitoring involves continuous ECG recording over a 24-48 hour period, allowing for the detection of intermittent or paroxysmal AF episodes.

4.3. Event Recorders:

Event recorders are portable ECG devices that can be activated by the patient to record symptomatic episodes of AF. They are particularly useful for detecting infrequent or transient AF.

4.4. Implantable Loop Recorders (ILRs):

ILRs are small, subcutaneous devices that continuously monitor heart rhythm and automatically record AF episodes. They are valuable for detecting asymptomatic AF and guiding anticoagulation decisions, especially in patients with cryptogenic stroke [21].

4.5. Mobile Health Technologies:

Mobile health (mHealth) technologies, such as smartwatches and smartphone-based ECG monitors, are increasingly being used for AF detection [22]. These devices offer convenient and accessible methods for monitoring heart rhythm and identifying potential AF episodes. While promising, the accuracy and reliability of mHealth devices vary, and confirmation with traditional ECG methods is essential.

4.6. Echocardiography:

Echocardiography is used to assess atrial size, left ventricular function, and the presence of structural heart disease, providing valuable information for risk stratification and treatment planning.

4.7. Cardiac Magnetic Resonance Imaging (MRI):

Cardiac MRI can provide detailed anatomical and functional information about the atria, including the extent of atrial fibrosis and scar tissue. It can also be used to guide catheter ablation procedures and assess the effectiveness of ablation therapy [23].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Current Treatment Options

The management of AF involves a multifaceted approach, including:

5.1. Rate Control:

Rate control aims to slow the ventricular rate to alleviate symptoms and improve hemodynamic function. Commonly used rate-control medications include:

• Beta-blockers: These drugs reduce heart rate by blocking the effects of adrenaline and noradrenaline on the heart.
• Calcium Channel Blockers: These drugs slow heart rate by blocking calcium channels in the heart cells.
• Digoxin: This drug slows heart rate by increasing vagal tone and slowing conduction through the AV node.

5.2. Rhythm Control:

Rhythm control aims to restore and maintain sinus rhythm, reducing the burden of AF and improving quality of life. Rhythm control strategies include:

• Antiarrhythmic Drugs: These drugs prevent AF by altering the electrical properties of the heart. Common antiarrhythmic drugs include amiodarone, flecainide, propafenone, and sotalol. However, these drugs can have significant side effects and may not be effective in all patients.
• Electrical Cardioversion: This procedure involves delivering an electrical shock to the chest to restore sinus rhythm. Electrical cardioversion is typically used for acute AF episodes or when pharmacological cardioversion is unsuccessful.
• Catheter Ablation: Catheter ablation is an invasive procedure that involves destroying or isolating the areas of the heart that are triggering or maintaining AF [24]. The most common target for ablation is the pulmonary veins. Catheter ablation has been shown to be more effective than antiarrhythmic drugs in maintaining sinus rhythm, particularly in symptomatic patients with paroxysmal AF [25].

5.3. Anticoagulation:

Anticoagulation is essential for reducing the risk of stroke in AF patients. The choice of anticoagulant depends on the patient’s individual risk factors, as assessed by the CHA2DS2-VASc score [26]. Anticoagulation options include:

• Warfarin: This drug inhibits the synthesis of vitamin K-dependent clotting factors. Warfarin requires regular monitoring of the international normalized ratio (INR) to ensure adequate anticoagulation.
• Direct Oral Anticoagulants (DOACs): These drugs directly inhibit specific clotting factors, such as thrombin (dabigatran) or factor Xa (rivaroxaban, apixaban, edoxaban). DOACs are generally preferred over warfarin due to their ease of use and lower risk of bleeding.

5.4. Surgical Ablation:

Surgical ablation, often performed during concomitant cardiac surgery, involves creating lesions in the atria to interrupt re-entrant circuits and prevent AF. The Cox-Maze procedure is the most common surgical ablation technique [27].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Emerging Therapeutic Strategies and the Role of Pulsed Field Ablation (PFA)

Despite advancements in AF management, current therapies have limitations, including incomplete efficacy, side effects, and procedural complications. Emerging therapeutic strategies are focused on addressing these limitations and improving patient outcomes. One promising area of research is the development of novel ablation techniques, such as pulsed field ablation (PFA).

6.1. Pulsed Field Ablation (PFA):

PFA is a novel ablation technique that uses short bursts of high-voltage electrical energy to create lesions in the heart tissue [28]. Unlike traditional radiofrequency ablation (RFA), which relies on thermal energy to create lesions, PFA utilizes a non-thermal mechanism of cell death called irreversible electroporation. This mechanism selectively targets cardiac cells while sparing surrounding structures, such as the esophagus and phrenic nerve, potentially reducing the risk of complications [29].

6.2. Mechanisms of PFA:

PFA involves delivering a series of short, high-voltage electrical pulses to the target tissue. These pulses create nanopores in the cell membrane, leading to cell swelling, disruption of cellular homeostasis, and ultimately, cell death. The selectivity of PFA for cardiac cells is attributed to the unique electrical properties of cardiac tissue and the ability to precisely control the energy delivery [30].

6.3. Advantages of PFA:

• Reduced Risk of Esophageal Injury: PFA spares the esophagus from thermal damage, reducing the risk of atrio-esophageal fistula, a rare but devastating complication of RFA.
• Reduced Risk of Phrenic Nerve Injury: PFA minimizes the risk of phrenic nerve injury by avoiding thermal damage to the nerve tissue.
• Faster Procedure Times: PFA may offer faster procedure times compared to RFA, due to the rapid and efficient creation of lesions.
• Potentially More Durable Lesions: Some preclinical studies suggest that PFA may create more durable lesions compared to RFA, potentially leading to improved long-term outcomes.

6.4. Clinical Evidence for PFA:

Early clinical trials have demonstrated promising results with PFA for AF ablation [31]. These studies have shown that PFA is safe and effective in achieving pulmonary vein isolation (PVI), with a low incidence of complications. Ongoing clinical trials are evaluating the long-term efficacy and safety of PFA compared to RFA in larger patient populations. Real-world data is also beginning to emerge, supporting the initial findings and highlighting the potential benefits of PFA in specific patient subgroups.

6.5. Other Emerging Therapeutic Strategies:

• Hybrid Ablation: Combining surgical and catheter ablation techniques to achieve more complete lesion sets and improve AF outcomes.
• Targeted Drug Delivery: Developing novel drug delivery systems to selectively target atrial tissue and enhance the efficacy of antiarrhythmic drugs.
• Gene Therapy: Exploring the potential of gene therapy to correct ion channel abnormalities and prevent atrial remodeling.
• Personalized Medicine: Tailoring AF management strategies to individual patient characteristics, including genetic factors, biomarkers, and imaging findings.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Potential Complications and Mitigation Strategies

Although advances in techniques and technologies have improved the safety profile of AF therapies, potential complications remain a concern [32]. These complications can arise from both pharmacological interventions and invasive procedures. It is essential to recognize these complications and implement appropriate mitigation strategies.

7.1. Complications of Anticoagulation:

• Bleeding: The most common complication of anticoagulation is bleeding, which can range from minor bruising to life-threatening hemorrhage. Risk factors for bleeding include advanced age, history of bleeding, renal impairment, and concomitant use of antiplatelet agents. Mitigation strategies include careful patient selection, dose adjustment based on renal function, and regular monitoring for bleeding signs.

7.2. Complications of Catheter Ablation:

• Pulmonary Vein Stenosis: Narrowing of the pulmonary veins after ablation can lead to pulmonary hypertension and shortness of breath. Mitigation strategies include careful ablation technique and avoiding excessive energy delivery near the PV ostia.
• Atrio-Esophageal Fistula: A rare but devastating complication involving a connection between the atrium and the esophagus. Mitigation strategies include monitoring esophageal temperature during ablation and using ablation techniques that minimize thermal injury to the esophagus.
• Phrenic Nerve Injury: Damage to the phrenic nerve can lead to diaphragmatic paralysis and shortness of breath. Mitigation strategies include careful mapping and avoiding ablation near the phrenic nerve.
• Stroke/TIA: Thromboembolic events can occur during or after catheter ablation. Mitigation strategies include periprocedural anticoagulation and careful management of potential thromboembolic sources.
• Cardiac Perforation/Tamponade: Puncture of the heart wall can lead to pericardial effusion and cardiac tamponade. Mitigation strategies include careful catheter manipulation and monitoring for signs of pericardial effusion.
• Groin Hematoma/Pseudoaneurysm: Bleeding or hematoma formation at the catheter insertion site. Mitigation strategies include careful vascular access and post-procedural compression.

7.3. Strategies for Minimizing Complications:

• Careful Patient Selection: Identifying patients who are most likely to benefit from the intervention and who have a low risk of complications.
• Experienced Operators: Performing procedures in centers with experienced operators and a high volume of AF ablation cases.
• Advanced Imaging Techniques: Using advanced imaging techniques, such as cardiac MRI, to guide ablation procedures and minimize the risk of complications.
• Periprocedural Anticoagulation: Providing adequate anticoagulation during and after the procedure to prevent thromboembolic events.
• Prompt Recognition and Management of Complications: Having protocols in place for the prompt recognition and management of potential complications.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

8. Future Directions and Research Priorities

Despite significant advances in AF management, several key challenges remain. Future research efforts should focus on addressing these challenges and improving patient outcomes. Key research priorities include:

8.1. Improving AF Detection and Prevention:

• Developing more sensitive and specific methods for detecting asymptomatic AF.
• Identifying and targeting individuals at high risk for AF to prevent the development of the arrhythmia.
• Investigating the role of lifestyle modifications and risk factor management in preventing AF.

8.2. Enhancing Ablation Techniques and Technologies:

• Optimizing PFA parameters and delivery techniques to improve lesion durability and reduce complications.
• Developing novel ablation technologies, such as laser ablation and high-intensity focused ultrasound (HIFU), to improve AF outcomes.
• Improving catheter mapping systems to create more accurate and detailed atrial maps, guiding ablation procedures and reducing the risk of complications.

8.3. Identifying Novel Therapeutic Targets:

• Investigating the role of inflammation, oxidative stress, and fibrosis in AF pathogenesis to identify novel therapeutic targets.
• Developing targeted therapies to modulate atrial remodeling and prevent AF progression.
• Exploring the potential of gene therapy and cell-based therapies to repair damaged atrial tissue and restore normal electrical function.

8.4. Personalizing AF Management:

• Developing biomarkers and predictive models to identify patients who are most likely to benefit from specific AF therapies.
• Tailoring treatment strategies to individual patient characteristics, including genetic factors, comorbidities, and lifestyle factors.
• Utilizing mHealth technologies and remote monitoring systems to personalize AF management and improve patient adherence.

8.5. Addressing the Burden of Persistent AF:

• Developing more effective strategies for managing persistent AF, including advanced ablation techniques and hybrid ablation approaches.
• Investigating the role of non-pulmonary vein targets in maintaining persistent AF.
• Developing novel pharmacological therapies to improve rhythm control in patients with persistent AF.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

9. Conclusion

Atrial fibrillation represents a significant and growing healthcare burden. While significant progress has been made in understanding its pathophysiology and developing effective treatment strategies, challenges remain in achieving long-term rhythm control and minimizing complications. Emerging therapeutic strategies, such as pulsed field ablation, hold promise for improving patient outcomes and addressing the limitations of current therapies. Future research efforts should focus on improving AF detection and prevention, enhancing ablation techniques, identifying novel therapeutic targets, and personalizing AF management to optimize patient care. The continued pursuit of innovative approaches is essential to alleviate the burden of AF and improve the lives of millions affected by this complex arrhythmia.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

[1] Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J. 2016;37(38):2893-2962.

[2] Colilla S, Crow A, Petkun W, Singer DE, Simon T, Liu X. Estimates of current and future prevalence and incidence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013;112(8):1142-1147.

[3] Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988.

[4] Kim MH, Johnston SS, Chu BC, Dalal M, Schulman KL. Estimation of the total incremental cost of atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes. 2011;4(3):313-320.

[5] Lafuente-Lafuente C, Longas-Tejero MA, Bergmann JF, Belmin J. Antiarrhythmic drugs for maintaining sinus rhythm after cardioversion of atrial fibrillation: a systematic review of randomised controlled trials. Age Ageing. 2006;35(3):216-223.

[6] Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2017;14(10):e275-e444.

[7] Jalife J, Kaur K. Atrial fibrillation: mechanistic insights from discrete experimental models. Circ Res. 2006;98(11):1342-1358.

[8] Haïssaguerre M, Jaïs P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998;339(10):659-666.

[9] Nathan H, Eliakim M. The junction between the left atrium and the pulmonary veins. An anatomic study of human hearts. Circulation. 1966;34(3):412-422.

[10] Allessie MA, Ausma J, Schalij MJ. Electrical, contractile and structural remodeling of the atrium during chronic atrial fibrillation. Eur Heart J. 1998;19(Suppl G):G15-G23.

[11] Burstein B, Nattel S. Atrial fibrosis: mechanisms and clinical implications in atrial fibrillation. J Am Coll Cardiol. 2008;51(8):802-809.

[12] Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92(7):1954-1968.

[13] Chung MK, Karliner JS, Hondeghem LM, et al. Anti-inflammatory effects of statins in patients with atrial fibrillation. Circulation. 2001;104(24):2886-2891.

[14] Carnes CA, Lentz SR, Embertson JR, Diers AD, Duryee MJ, Domann FE. Acetyl-L-carnitine favorably modifies biomarkers of oxidative stress and improves clinical status in canine model of pacing-induced heart failure. J Card Fail. 2008;14(2):156-167.

[15] Shen MJ, Zipes DP. Role of the autonomic nervous system in modulating cardiac arrhythmias. Circ Res. 2014;114(6):1020-1039.

[16] Benjamin EJ, Levy D, Vaziri SM, D’Agostino RB, Larson MG, Newell JB, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort. The Framingham Heart Study. JAMA. 1994;271(11):840-844.

[17] Ellinor PT, Low AF, MacRae CA, et al. Common genetic variation and risk of atrial fibrillation. N Engl J Med. 2007;357(9):908-918.

[18] Gami AS, Pressman G, Caples SM, Kanagala R, Gard JJ, Davison DE, Somers VK. Association of atrial fibrillation and obstructive sleep apnea. Circulation. 2004;110(4):364-371.

[19] ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). Circulation. 2006;114(7):e257-e354.

[20] Page RL, Tilz RR, Kalman JM, et al. 2020 ESC Guidelines for management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021;42(5):373-498.

[21] Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014;370(26):2478-2486.

[22] Perez MV, Mahaffey KW, Quirk B, et al. Accuracy of a wrist-worn wearable device for detecting atrial fibrillation. JAMA Cardiol. 2019;4(5):461-468.

[23] McGann C, Akoum N, Patel A, et al. Atrial fibrosis quantified by delayed enhancement MRI is an independent predictor of atrial fibrillation recurrence after pulmonary vein isolation. J Am Coll Cardiol. 2009;54(3):210-217.

[24] Haïssaguerre M, Jaïs P, Shah DC, et al. Catheter ablation of atrial fibrillation targeting the pulmonary veins: concept, results, and future directions. Pacing Clin Electrophysiol. 2000;23(11 Pt 2):1608-1612.

[25] Wilber DJ, Pappone C, Neuzil P, et al. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2003;289(3):387-394.

[26] Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010;137(2):263-272.

[27] Cox JL, Boineau JP, Schuessler RB, Cain ME, Lindsay BD, Corr PB, Barner HB, Lappas DG. Modification of the maze procedure for atrial flutter and atrial fibrillation. I. Rationale and surgical results. J Thorac Cardiovasc Surg. 1995;110(2):473-81; discussion 481-2.

[28] Reddy VY, Neuzil P, Koruth J, et al. Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation. J Am Coll Cardiol. 2019;74(9):1125-1135.

[29] Stewart MT, Pluymaekers NA, Weerts J, et al. Esophageal injury following atrial fibrillation ablation: characterization using endoscopic ultrasound and magnetic resonance imaging. Heart Rhythm. 2011;8(11):1657-1663.

[30] Witt CM, Ramirez DA, Reddy VY. Pulsed Field Ablation: Biophysics, Technology, and Early Clinical Results. Arrhythm Electrophysiol Rev. 2021;10(1):41-47.

[31] Reddy VY, Schmidt M, Neuzil P, et al. Paroxysmal Atrial Fibrillation Ablation With a Novel Multi-Electrode Pulsed Field Ablation Catheter: Acute and 3-Month Outcomes. Circ Arrhythm Electrophysiol. 2023;16(3):e011728.

[32] Cappato R, Marchlinski FE, Hranitzky PM, et al. Unwanted effects of catheter ablation for atrial fibrillation. Circulation. 2010;121(6):824-833.